Testosterone levels and coronary lesion complexity in young men
Impact of Serum Testosterone Level on Angiographic Complexity of Coronary Lesions in Premature Ischemic Egyptian Males
We will test whether blood testosterone levels are linked to how complex coronary artery blockages are in men under 45 with premature ischemic heart disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | N/A to 45 Years |
| Sex | Male |
| Sponsor | Sohag University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Sohag) |
| Trial ID | NCT07076771 on ClinicalTrials.gov |
What this trial studies
This observational study enrolls men under 45 with premature ischemic heart disease who are scheduled for elective coronary angiography. Investigators will measure serum testosterone and determine lesion complexity using the SYNTAX score from the angiograms. The analysis will look for associations between testosterone level and angiographic complexity while adjusting for traditional cardiovascular risk factors. Results aim to clarify whether hormonal status relates to the severity and complexity of early-onset coronary artery disease.
Who should consider this trial
Good fit: Men younger than 45 diagnosed with premature ischemic heart disease who are undergoing elective coronary angiography and have not used testosterone therapy or anabolic steroids.
Not a fit: Patients with a recent acute coronary syndrome, prior hypogonadism or testosterone/anabolic steroid use, active cancer, significant liver or kidney disease, or on medications that affect sex hormones are excluded and unlikely to benefit.
Why it matters
Potential benefit: If a link is confirmed, measuring testosterone could help identify young men at higher risk of complex coronary disease and inform early risk-reduction strategies.
How similar studies have performed: Prior observational work has linked low testosterone to worse metabolic and cardiovascular risk profiles, but direct evidence tying testosterone to angiographic lesion complexity is limited, so this is largely exploratory.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male patients aged \<45 years. * Diagnosed with premature ischemic heart disease. * Undergoing elective coronary angiography for suspected coronary artery disease (CAD) . Exclusion Criteria: * History of acute coronary syndrome within the preceding 3 months. * Prior diagnosis of hypogonadism or history of testosterone replacement therapy or anabolic steroid use. * Active neoplasm or history of chemotherapy. * Known hepatic cirrhosis, chronic kidney disease, or end-stage renal disease. * Use of medications known to affect sex hormone levels (e.g., spironolactone, ketoconazole). * Endocrine disorders such as sickle cell anemia or celiac disease.
Where this trial is running
Sohag
- Sohag University — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: Remon S Adly, MD
- Email: remonsaleh@yahoo.com
- Phone: 00201221878986
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.